MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
1.640
-0.190
-10.38%
After Hours: 1.720 +0.08 +4.88% 19:24 11/11 EST
OPEN
1.800
PREV CLOSE
1.830
HIGH
1.853
LOW
1.630
VOLUME
53.58K
TURNOVER
--
52 WEEK HIGH
127.50
52 WEEK LOW
1.630
MARKET CAP
3.15M
P/E (TTM)
-0.0134
1D
5D
1M
3M
1Y
5Y
1D
Medicus Pharma downgraded to Hold from Buy at Brookline
TipRanks · 15h ago
Medicus Pharma’s SkinJect SPAC and CD228V ADC Catalysts Support Buy Rating; $15 Price Target Maintained
TipRanks · 1d ago
Medicus Prioritizes CD228V in Capital-Efficiency Strategy
TipRanks · 2d ago
Medicus to highlight rational for CD228V co-development, license agreement
TipRanks · 2d ago
Medicus Pharma to highlight rationale for proposed SkinJect SPAC transaction
TipRanks · 2d ago
Medicus anticipates ‘substantial’ reduction in opex in coming quarters
TipRanks · 2d ago
Weekly Report: what happened at MDCX last week (1102-1106)?
Weekly Report · 2d ago
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
Barchart · 3d ago
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.